Business Wire

GLOBAL-HEALTHCARE-EXCHNG

31.7.2017 08:02:09 CEST | Business Wire | Press release

Share
New GHX eInvoicing Solution Helps Healthcare Suppliers Meet EU Directives

Global Healthcare Exchange, LLC (GHX) today announced a pan-European eInvoicing solution designed to help healthcare suppliers meet electronic invoicing regulations. With the new GHX eInvoicing, suppliers can issue and send compliant invoices to healthcare provider customers and governments across Europe from one connection.

The GHX solution, which works with the GHX Exchange Services, supports the eInvoicing requirements for integrity, authenticity, legibility and archiving under the VAT Directive 2006/112/ED and the Electronic Invoice Directive 2010/45/EU. It also provides an easy-to-use portal for customers to access invoices electronically, even those with no EDI capabilities.

“Moving away from paper invoices and manual invoicing processes will be an advantage for healthcare suppliers across Europe. However, navigating through the complexity of the European marketplace and complying with the various regulations of the EU member states can be a significant challenge,” said Dr. Nedzad Fajic, president, GHX Europe. “The new GHX eInvoicing solution with its eInvoicing portal will deliver better visibility into the entire order-to-cash cycle, reduce manual processing and help suppliers deliver a better customer experience.”

By November 27, 2018, all EU countries are required to adopt Directive 2014/55/EU into local law, which calls for all invoices sent to hospitals to have ‘authenticity of origin, content integrity and eligibility’ by having business controls and/or electronic invoicing technology in place. GHX eInvoicing is designed to meet those requirements with a simple and efficient solution.

eInvoices will be sent through a supplier’s existing GHX Global Exchange connection and checked to validate content is in the required fields. The eInvoice will then be delivered to the relevant customers and government access points across Europe, with digital signatures and archiving where required for compliance. Non-EDI capable customers will also be able to receive invoices through the new eInvoicing portal, where they can manage and retrieve invoices in PDF format, as well as receive them via email.

The new eInvoicing solution includes:

  • Enabling any electronic invoice to be converted in the appropriate format with the appropriate information to comply with EU country-specific invoicing regulations.
  • Interoperates with the GHX Global Exchange and other GHX solutions for the full order-to-cash cycle to provide a one-stop solution for eInvoicing in Europe.
  • Automatically sends the compliant invoice to the appropriate public administration access point, as well as the appropriate customers.
  • A dedicated online portal that allows even non-EDI capable customers to see and download invoices.
  • Provides suppliers and their customers with access to current and past invoices all in one place.
  • Includes tracking and monitoring capabilities.

Availability

GHX eInvoicing is now generally available across Europe. For more information, contact Marcus Schiewe, Head of Supplier Sales, Europe, +49 (0) 211 301 88 300.

About GHX Europe

Global Healthcare Exchange, LLC (GHX), with its European headquarters in Brussels, drives costs out of healthcare with cloud-based supply chain management technology and services to help enable better patient care and savings by maximizing automation, efficiency, and accuracy of business processes. GHX offers European healthcare providers and suppliers an open and neutral electronic trading exchange that delivers procurement and accounts payable automation as well as other supply chain-related tools and services. For more information, visit www.ghx.com/europe/en and The Healthcare Hub .

Contact:

Tier One Partners
Paula Timko, 508-826-1508
ptimko@tieronepr.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye